CEACAM5 and non-small cell lung carcinoma: Specifically, AUC for Stage III/IV NSCLC patients was 0.907, a very good measurement as compared to other serum-based NSCLC biomarkers, such as CYFRA21-1, CA-125 or Carcinoembryonic antigen (CEA) (Cedrés et al., 2011; Grunnet and Sorensen, 2012).